Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Héctor Peinado(Centro Nacional de Biotecnología), David Lyden(Cornell University), Margaret K. Callahan(Cornell University), Caitlin Williams(Cornell University), Irina Matei(Cornell University), Rosandra N. Kaplan(National Cancer Institute), Guillermo García‐Santos(Hospital Universitario Central de Asturias), Benjamin A. Garcia(Washington University in St. Louis), Vilma R. Martins(Biotech (Brazil)), Jacqueline Bromberg(Memorial Sloan Kettering Cancer Center), Mary S. Brady(Memorial Sloan Kettering Cancer Center), Yibin Kang(Rutgers, The State University of New Jersey), Bruno Costa‐Silva(AC Camargo Hospital), Maša Alečković(Princeton University), Jedd D. Wolchok(Cornell University), Gema Moreno‐Bueno(Centro de Investigación Biomédica en Red de Cáncer), Cyrus M. Ghajar(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Marta Hergueta‐Redondo(Spanish National Cancer Research Centre), Ayuko Nitadori-Hoshino(Children's Cancer and Blood Foundation), Karen Badal(Children's Cancer and Blood Foundation), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Jianda Yuan, Johan Skog(Exosome Diagnostics (United States)), Caitlin Hoffman(Medical College of Wisconsin), Simon Lavotshkin(Columbia University)
Cited by 3,700
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k